ACAD (ACADIA Pharmaceuticals Inc.) stock: $27.29, $4.70B market cap, $956.5M cash, $3.75B EV, $5.61B fully diluted market cap. Next expected readout: Aug-27. Lead program: ACP-204 (Alzheimer's Disease Psychosis), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$3,745.7M
Balance sheet
| Cash | $956.5M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $956.5M |
|---|
| Enterprise value | $3,745.7M |
|---|
| Basic shares | 172.1M shares |
|---|
| Fully diluted shares | 205.7M shares |
|---|
| Fully diluted market cap | $5,613.3M |
|---|
| Cash per share | $5.56 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading ACAD daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Sep 12 - Oct 24 | ACP-211 | Phase 2 | Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant | — |
| Feb 12 - Mar 25 | ACP-204 | Phase 3 | Alzheimer's Disease Psychosis | September to October 2026 |
| Mar 14 - Apr 25 | ACP-204 | Phase 2 | Lewy Body Dementia Psychosis | — |
| Mar 15 - Apr 26 | ACP-204 | Phase 3 | Lewy Body Dementia Psychosis | — |
| May 13 - Jun 24 | ACP-204 | Phase 3 | Alzheimer's Disease Psychosis | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
Pimavanserin (NUPLAZID)
Approved · Active
Target 5-HT2A receptor
Indications- Parkinson's disease psychosis (PDP) (Approved)
Status note First and only FDA-approved drug for hallucinations and delusions associated with PDP (approved April 2016; launched May 2016).
Trofinetide (DAYBUE)
Approved · Active
Aliases DAYBU, DAYBUE STIX
Target IGF-1
Partnerships Neuren Pharmaceuticals: $10M upfront (2018, North America) + up to $455M milestones, tiered double-digit royalties; expanded Jul 2023: $100M upfront, up to $426.3M milestones (trofinetide ex-NA), mid-teens to low-twenties royalties ex-NA; Neuren entitled to one-third of $146.5M PRV sale proceeds.
Status note First and only approved Rett syndrome therapy: US Mar 2023, Canada Oct 2024, Israel Dec 2025; DAYBUE STIX approved Dec 2025 (limited availability Q1 2026, broader launch Q2 2026). CHMP adopted positive opinion Jun 2026 (re-examination) recommending EU marketing authorization for DAYBU; EC decision pending.
Remlifanserin
Phase 2/3 · Active
Target serotonergic system
Indications- Alzheimer's disease psychosis (ADP) (Phase 2/3)
- Lewy Body Dementia psychosis (LBDP) (Phase 2)
Status note Most advanced current product candidate per this filing. RADIANT ADP program: Phase 2 portion enrollment complete, Phase 3 portion screening/enrolling (judgment call PHASE_2_3); additional Phase 2 study in LBDP initiated Sep 2025. FDA Fast Track granted Jul 2026 for ADP.
ACP-211
Phase 2 · Active
Indications- Major depressive disorder (MDD) (Phase 2)
Status note Phase 2 study in MDD initiated Q4 2025. 10-Q states no topline timing.
ACP-711
Phase 1 · Active
Target GABAA-a3
Partnerships Saniona A/S: $28M upfront; up to $582M milestones ($147M development/commercial for first and second indications + $435M sales thresholds); tiered royalties mid-single digits to low double digits.
Indications- Essential tremor (Phase 1)
Status note Highly selective GABAA-a3 positive allosteric modulator; Phase 1 complete; Phase 2 in essential tremor expected to begin in 2027.
ACP-271
Phase 1 · Active
Target GPR88
Status note GPR88 agonist; first-in-human study in healthy volunteers initiated Q1 2026. 10-Q states no indication.
NNZ-2591
Stage not disclosed · Active
Aliases ercanetide
Partnerships Neuren Pharmaceuticals: global rights under Jul 2023 expanded agreement; up to $831.3M NNZ-2591 development/sales milestones; royalties identical to trofinetide tiers.
Indications- Rett syndrome (Stage not disclosed)
- Fragile X syndrome (Stage not disclosed)
Status note Neuren development candidate; 10-Q states licensed global rights in Rett syndrome and Fragile X syndrome but no clinical stage.
SYNGAP1 program
Stage not disclosed · Active Modality: RNA-based medicine
Target SYNGAP1
Partnerships Stoke Therapeutics: $60M upfront; up to $245M milestones; 50/50 worldwide cost/profit share on the SYNGAP1 program.
Indications- SYNGAP1-related neurodevelopmental disease (Stage not disclosed)
Status note RNA-based medicines collaboration for severe and rare genetic neurodevelopmental CNS diseases; 10-Q states no stage.
MECP2 program
Stage not disclosed · Terminated
Target MECP2
Partnerships Stoke Therapeutics (licenses terminating; activities winding down).
Indications- Rett syndrome (Stage not disclosed)
Status note Discontinued May 2025; licenses to the MECP2 program terminating and activities winding down.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.